Novo Nordisk’s stock has been falling due to recent clinical setbacks and disappointing results. However, upcoming catalysts could boost its price. Despite challenges, the company’s pipeline and lineup make it appealing, especially at current levels. Novo Nordisk faces competition from Eli Lilly but has potential in the growing anti-obesity medication market.

The company’s stock has dropped by 40% since January, but patient investors could still see strong returns. Novo Nordisk’s deep pipeline, including weight management treatments like Wegovy, positions it well for future success. The stock is trading at a reasonable valuation compared to the industry average. Despite recent setbacks, Novo Nordisk remains a promising investment option.

Read more at Yahoo Finance: 1 Stock Down 40% This Year to Buy and Hold